Therapeutic banner
Therapeutic banner

Transthyretin (ATTR) Amyloidosis

View the latest scientific data presented at congress events in the past 2 years and discover peer-reviewed publications related to ATTR Amyloidosis.
The information on this page pertains to select congress and publication resources. It is not intended to serve as a comprehensive list of all congress and publications resources.

Explore Therapeutic Areas

Congresses

View More Arrow
Congress-EU-ATTR-Mobile

Transthyretin Amyloidosis (ATTR)

European ATTR Amyloidosis Meeting (EU-ATTR) 2025

September 25-26, 2025 ITALY

View Details
Congress-CAPT-Mobile

Transthyretin Amyloidosis (ATTR)

Canadian Association for Population Therapeutics (CAPT) 2025

September 22-23, 2025 CANADA

View Details
Congress-ESC-Mobile

Transthyretin Amyloidosis (ATTR)

European Society of Cardiology (ESC) 2025

August 29 - September 1, 2025 SPAIN

View Details

Publications

View More Arrow

Transthyretin Amyloidosis (ATTR)

Vutrisiran in Transthyretin Amyloidosis: A Pooled Safety Analysis of HELIOS-A and HELIOS-B

JACC: Advances

Author(s)

Ronald M. Witteles, Pablo Garcia-Pavia, Caroline Morbach, et al

August 2025

Transthyretin Amyloidosis (ATTR)

Effects of Vutrisiran on Cardiac Structure and Function in Patients with Transthyretin Amyloidosis with Cardiomyopathy: Secondary Outcomes of the HELIOS-B Trial

Nature Medicine

Author(s)

Karola S. Jering, Marianna Fontana, Olivier Lairez, et al

August 2025

Transthyretin Amyloidosis (ATTR)

Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B

Journal of the American College of Cardiology

Author(s)

Mathew S. Maurer, John L. Berk, Thibaud Damy, et al

August 2025

Transthyretin Amyloidosis (ATTR)

Effects of Vutrisiran on Cardiac Function and Outcomes in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Journal of the American College of Cardiology

Author(s)

Karola S. Jering, Marianna Fontana, Hicham Skali, et al

August 2025

Transthyretin Amyloidosis (ATTR)

Benefits of Patisiran on Functional Capacity in ATTR Cardiac Amyloidosis: Post Hoc Analysis of APOLLO-B

JACC: Advances

Author(s)

John L Berk, Olivier Lairez, Pedro Schwartzmann, et al

June 2025

Transthyretin Amyloidosis (ATTR)

Realizing the therapeutic potential of rapid knockdown of transthyretin via RNA interference in transthyretin amyloidosis

Molecular Therapy Nucleic Acids

Author(s)

Martha Grogan, Farooq H. Sheikh, Brett W. Sperry, et al

June 2025